Compare · JNJ vs NRSN
JNJ vs NRSN
Side-by-side comparison of Johnson & Johnson (JNJ) and NeuroSense Therapeutics Ltd. (NRSN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and NRSN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 25191.9x NRSN ($24.2M).
- Over the past year, JNJ is up 54.6% and NRSN is down 64.9% - JNJ leads by 119.5 points.
- JNJ has been more active in the news (10 items in the past 4 weeks vs 6 for NRSN).
- JNJ has more recent analyst coverage (25 ratings vs 1 for NRSN).
- Company
- Johnson & Johnson
- NeuroSense Therapeutics Ltd.
- Price
- $253.01+1.39%
- $0.71+0.04%
- Market cap
- $609.12B
- $24.2M
- 1M return
- +7.55%
- +5.74%
- 1Y return
- +54.56%
- -64.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 6
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
Latest NRSN
- NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
- EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
- Chief Executive Officer Ben-Noon Alon bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 6% to 4,534,233 units (SEC Form 4)
- Chief Financial Officer Eisenberg Or bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 20% to 1,504,050 units (SEC Form 4)
- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.